Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1

Conditions

Leukemia, Myeloid, Acute 24Breast Neoplasms 15Carcinoma, Non-Small-Cell Lung 10Sarcoma 9Myelodysplastic Syndromes 9Stomach Neoplasms 8Multiple Myeloma 7Leukemia, Myelomonocytic, Chronic 7Myeloproliferative Disorders 6Uterine Cervical Neoplasms 5Lymphoma, Large B-Cell, Diffuse 5Lung Neoplasms 5Recurrence 4Prostatic Neoplasms 4Neoplasms 4Melanoma 4Leukemia, Monocytic, Acute 4Head and Neck Neoplasms 4Esophageal Squamous Cell Carcinoma 4Esophageal Neoplasms 4Carcinoma, Hepatocellular 4Biliary Tract Neoplasms 4Advanced Solid Tumour 4Stomatitis 3Squamous Cell Carcinoma of Head and Neck 3Ovarian Neoplasms 3Neuroendocrine Tumors 3Mucositis 3Leukemia, Myelomonocytic, Acute 3Cholangiocarcinoma 3

Interventions

Paclitaxel 6Doxorubicin 6Gemcitabine 4Bevacizumab 4pembrolizumab 3pazopanib 3durvalumab 3Sorafenib 3Docetaxel 3trebananib 2spartalizumab 2cemiplimab 2brostallicin 2Propranolol 2Nivolumab 2Magnetic Resonance Spectroscopy 2Ipilimumab 2Imatinib Mesylate 2Ifosfamide 2Carboplatin 23-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 2zanidatamab 1veliparib 1tucatinib 1trilaciclib 1tremelimumab 1trastuzumab duocarmazine 1temsirolimus 1talimogene laherparepvec 1talazoparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Hemangiosarcoma × Injections × Clear all
NCT06277154 2025-07-24

MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma

HRYZ Biotech Co.

Phase 2 Recruiting
148 enrolled
GynecologicSarcoma

Fibrosarcoma, Hemangiosarcoma, Leiomyosarcoma, Liposarcoma, Sarcoma, Sarcoma, Synovial, Sarcoma, Endometrial Stromal, Neurofibrosarcoma, Histiocytoma, Malignant Fibrous, Desmoplastic Small Round Cell Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡